(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 14.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Niagen Bioscience's revenue in 2025 is $124,709,000.On average, 7 Wall Street analysts forecast NAGE's revenue for 2025 to be $10,362,029,088, with the lowest NAGE revenue forecast at $9,860,846,535, and the highest NAGE revenue forecast at $10,773,030,704. On average, 6 Wall Street analysts forecast NAGE's revenue for 2026 to be $12,472,103,403, with the lowest NAGE revenue forecast at $11,871,961,238, and the highest NAGE revenue forecast at $12,988,449,122.
In 2027, NAGE is forecast to generate $14,961,256,878 in revenue, with the lowest revenue forecast at $14,343,557,362 and the highest revenue forecast at $15,433,709,221.